Sphingosine kinase and sphingosine-1-phosphate receptor signaling pathway in inflammatory gastrointestinal disease and cancers: A novel therapeutic target

Sukocheva, Olga; Furuya, Hideki; Ng, Mei Li; Friedemann, Markus; Menschikowski, Mario; Tarasov, Vadim V.; Chubarev, Vladimir N.; Клочков, С. Г.; Neganova, Margarita E.; Mangoni, Arduino A.; Aliev, Gjumrakch; Bishayee, Anupam

doi:10.1016/j.pharmthera.2019.107464

Cited by 107 publications

(106 citation statements)

References 194 publications

Supporting

Mentioning

104

Contrasting

Order By: Relevance

“…S1P is an important bioactive lipid mediator, associated with various stress conditions and diseases [ 25 , 26 , 27 ]. S1P and its precursor, ceramide, are reciprocal regulators of cellular fate.…”

Section: Discussionmentioning

confidence: 99%

Serum Metabolomic Alterations Associated with Cesium-137 Internal Emitter Delivered in Various Dose Rates

Lin

Laiakis

et al. 2020

Metabolites

View full text Add to dashboard Cite

Our laboratory and others have use radiation metabolomics to assess responses in order to develop biomarkers reflecting exposure and level of injury. To expand the types of exposure and compare to previously published results, metabolomic analysis has been carried out using serum samples from mice exposed to 137Cs internal emitters. Animals were injected intraperitoneally with 137CsCl solutions of varying radioactivity, and the absorbed doses were calculated. To determine the dose rate effect, serum samples were collected at 2, 3, 5, 7, and 14 days after injection. Based on the time for each group receiving the cumulative dose of 4 Gy, the dose rate for each group was determined. The dose rates analyzed were 0.16 Gy/day (low), 0.69 Gy/day (medium), and 1.25 Gy/day (high). The results indicated that at a cumulative dose of 4 Gy, the low dose rate group had the least number of statistically significantly differential spectral features. Some identified metabolites showed common changes for different dose rates. For example, significantly altered levels of oleamide and sphingosine 1-phosphate were seen in all three groups. On the other hand, the intensity of three amino acids, Isoleucine, Phenylalanine and Arginine, significantly decreased only in the medium dose rate group. These findings have the potential to be used in assessing the exposure and the biological effects of internal emitters.

show abstract

Section: Discussionmentioning

confidence: 99%

Serum Metabolomic Alterations Associated with Cesium-137 Internal Emitter Delivered in Various Dose Rates

Lin

Laiakis

et al. 2020

Metabolites

View full text Add to dashboard Cite

show abstract

“…Estrogen (the growth-stimulating hormone in breast cancer cells) was shown to stimulate endothelial cell growth via S1PR1 [ 7 , 8 ]. In the tumor microenvironment, S1P exhibits multiple functions: (a) it increases the survival of macrophages; (b) it serves as the “come-and-get-me” signal of dead cells, attracting and enhancing macrophage migration by combining with S1PR1; (c) it stimulates the polarization of TAM/M2 macrophages by activating S1PR1/2/4 [ 9 – 11 ]. Accumulating evidence demonstrated that tumor progression requires new blood vessel growth, which is achieved by producing angiogenic factors that can activate vascular endothelial cells [ 12 ].…”

Section: Introductionmentioning

confidence: 99%

Prognostic value of S1PR1 and its correlation with immune infiltrates in breast and lung cancers

Xie

Yang

et al. 2020

BMC Cancer

View full text Add to dashboard Cite

Background: Sphingosine-1-phosphate receptor (S1PR1) is involved in vascular development, a key process in tumorigenesis. This study aimed to evaluate its roles in tumor development and prognosis. Methods: S1PR1 expression levels were analyzed using TIMER and Oncomine database, and the prognostic significance of S1PR1 was assessed using PrognoScan and Kaplan-Meier plotter databases. The relationship between S1PR1 and tumor-infiltrated immune cells was analyzed using TIMER. Results: S1PR1 expression was remarkably lower in breast and lung cancer tissues than in the corresponding normal tissues. Lower expression was related to poor overall survival and disease-free survival in breast invasive carcinoma (BRCA), lung adenocarcinoma (LUAD), and lung squamous cell carcinoma (LUSC). A functional network analysis confirmed the function of S1PR1 in regulating vasculogenesis. In addition, S1PR1 levels were significantly negative with regard to the tumor purity of BRCA (r = − 0.

show abstract

“…There is a wealth of evidence to support the involvement of deregulated production and removal of S1P in the ‘hallmarks of cancer’ [1,2,23,24]. Recent reviews which focus on the role of S1P in specific cancer types are available (e.g., breast [25], ovarian [26], gastrointestinal [27], hepatocellular carcinoma [28], glioblastoma [29]). Regardless of the cancer type, S1P is involved in tumour/stromal cell communication, the migration and invasiveness of cancer cells into the niche microenvironment, neovascularisation and metastasis, which are hallmarks of cancer that lead to patient mortality.…”

Section: Role Of S1p In Tumour Neovascularisation and Metastasismentioning

confidence: 99%

Recent advances in the role of sphingosine 1‐phosphate in cancer

Pyne

2020

FEBS Letters

View full text Add to dashboard Cite

Sphingosine 1-phosphate (S1P) is a bioactive lipid that binds to a family of G protein-coupled receptors (S1P 1-5) and intracellular targets, such as HDAC1/ 2, that are functional in normal and pathophysiologic cell biology. There is a significant role for sphingosine 1-phosphate in cancer underpinning the socalled hallmarks, such as transformation and replicative immortality. In this review, we survey the most recent developments concerning the role of sphingosine 1-phosphate receptors, sphingosine kinase and S1P lyase in cancer and the prognostic indications of these receptors and enzymes in terms of diseasespecific survival and recurrence. We also provide evidence for identification of new therapeutic approaches targeting sphingosine 1-phosphate to prevent neovascularisation, to revert aggressive and drug-resistant cancers to more amenable forms sensitive to chemotherapy, and to induce cytotoxicity in cancer cells. Finally, we briefly describe current advances in the development of isoform-specific inhibitors of sphingosine kinases for potential use in the treatment of various cancers, where these enzymes have a predominant role. This review will therefore highlight sphingosine 1-phosphate signalling as a promising translational target for precision medicine in stratified cancer patients.

show abstract

Sphingosine kinase and sphingosine-1-phosphate receptor signaling pathway in inflammatory gastrointestinal disease and cancers: A novel therapeutic target

Cited by 107 publications

References 194 publications

Serum Metabolomic Alterations Associated with Cesium-137 Internal Emitter Delivered in Various Dose Rates

Serum Metabolomic Alterations Associated with Cesium-137 Internal Emitter Delivered in Various Dose Rates

Prognostic value of S1PR1 and its correlation with immune infiltrates in breast and lung cancers

Recent advances in the role of sphingosine 1‐phosphate in cancer

Contact Info

Product

Resources

About